FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. TSRI 419.0 Con 1	SERIAL NO. 09/081,522
	APPLICANT Brooks, et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE May 19, 1998	GROUP 1644

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
PG		5,575,815	11/19/96	Slepian, et al.			
		5,849,692	12/15/98	Jonczyk, et al.			
		5,968,902	10/19/99	Scarborough, et al.			
		5,981,478	11/9/99	Ruoslahti, et al.			
		5,866,540	2/2/99	Jonczyk, et al.			
		5,135,919	8/4/92	Folkman, et al.			

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
		95/28426	10/26/95	PCT			
		97/14716	4/24/97	PCT			
		0 770 622 A	5/2/97	EPO			
		89/06536	7/27/89	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	1	Matsuno, et al., Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation, 1994, *Circulation*, 90(5):2203-2205.
	2	Timar, et al., The antimetabolite tiazofurin (TR) inhibits glycoconjugate biosynthesis and invasiveness of tumour cells, 1996, *Eur. J. Cancer*, 32A(1):152-159.
	3	Aimes, et al., Cloning of a 72 kDa matrix metalloproteinase (gelatinase) from chicken embryo fibroblasts using gene family PCR: expression of the gelatinase increases upon malignant transformation, 1994, Biochem J., 300:729-736.
	4	Friedlander, et al., Definition of two angiogenic pathways by distinct αv integrins, 1995, *Science*, 270:1500-1502.
	5	Pfaff, et al., Comparison of disintegrins with limited variation in the RGD loop in their binding to purified integrins αIIbβ3, αvβ3 and α5β1 and in cell adhesion inhibition, 1994, *Cell Adhes. Commun.*, 2(6):491-501.
	6	Smith, et al., Interaction of integrins αvβ3 and glycoprotein IIb-IIIa with fibrinogen, 1990, *J. Biol. Chem.*, 265:12267-12271.
	7	Mueller, et al., Pre-clinical therapy of human melanoma with morpholino-doxorubicin conjugated to a monoclonal antibody directed against an integrin on melanoma cells, *Antibody, Immunoconjugates, and Radiopharmaceuticals*, 1991, 4(2):99-106.
	8	Ossowski, et al., Experimental model for quantitative study of metastasis, 1980, *Cancer Res.*, 40:2300-2309.
PG	9	Drake, et al., A antagonist of integrin αvβ3 prevent maturation of blood vessels during embryonic neovascularization, 1995, *J. Cell Sci.*, 108:2655-2661.

EXAMINER	DATE CONSIDERED
PHILIP GAMBEL 5/28/02	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. TSRI 419.0 Con 1	SERIAL NO. 09/081,522
	APPLICANT Brooks, et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE May 19, 1998	GROUP 1644

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
M		95/14714	6/1/95	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

M	10	Hammes, et al., Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization, 1996, *Nature Med.*, 2(5):529-533.
	11	Brooks, et al., Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels, 1994, *Cell*, 79:1157-1164.
	12	Clark, et al, Transient functional expression of αvβ3 on vascular cells during wound repair, 1996, *Am. J Pathol.*, 148:1407-1421.
	13	Bauer, et al., In vitro model of angiogenesis using a human endothelium-derived permanent cell line: contributions of induced gene expression, G-proteins and integrins, 1992, *J. Cell. Physiol.*, 153:437-449.
	14	Ingber, Extracellular matrix as a solid state regulator of angiogenesis: identification of new targets for anti-cancer therapy, 1992, *Seminars in Cancer Biology*, 3:57-63.
	15	Hardan, et al., Inhibition of metastatic cell colonization in murine lungs and tumor-induced morbidity by non-peptidic Arg-Gly-Asp mimetics, 1993, *Intl. J. Cancer*, 55:1023-1028.
	16	Hynes, Integrins: versatility, modulation, and signaling in cell adhesion, 1992, *Cell*, 69:11-25.
M	17	Lehmann, et al., A monoclonal antibody inhibits adhesion to fibronectin and vitronectin of a colon carcinoma cell line and recognizes the integrins αvβ3, αvβ5 and αvβ6, 1994, *Cancer Res.*, 54:2102-2107.

EXAMINER	DATE CONSIDERED
Phillip Gambel 5/28/04	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. TSRI 419.0 Con 1	SERIAL NO. 09/081,522
	APPLICANT Brooks, et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE May 19, 1998	GROUP 1644

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

N	18	Pierschbacher, et al., Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion, 1987, *J. Biol. Chem.*, 262:17294-17296.
	19	Folkman, et al., Angiogenesis, 1992, *J. Biol. Chem.*, 267:10931-10934.
	20	Teicher, et al., Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents, 1994, *Intl. J. Cancer*, 57:920-925.
N	21	Saiki, et al., Inhibition of tumor angiogenesis by a synthetic cell-adhesive polypeptide containing the Arg-Gly-Asp (RGD) sequence of fibronectin, poly (RGD), 1990, *Jpn. J. Cancer Res.*, 81:668-675.
	22	
	23	
	24	
	25	
	26	

EXAMINER	DATE CONSIDERED
PHILIP GAMBEL 5/28/02	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.